Understanding the pharmacokinetics of prodrug and metabolite

Seungil Cho and Young-Ran Yoon

Molecular Diagnostics and Imaging Center, School of Medicine, Kyungpook National University; Clinical Trial Center, Kyungpook National University Hospital, Daegu 41944, Korea

*Correspondence: S. Cho; Tel: +82-53-200-6358, Fax: +82-53-422-4950, E-mail: chosi1@gmail.com
Y-R. Yoon; Tel: +82-53-420-4950, Fax: +82-53-426-4944, E-mail: yry@knu.ac.kr

Introduction

Prodrug is a pharmacologically inactive derivative of an active drug and undergoes in vivo biotransformation to release the active drug by chemical or enzymatic cleavages.[1-3] A prodrug strategy is typically used when a pharmacologically active drug has poor solubility or permeability.[1,2] Various chemically or enzymatically labile functional groups have been introduced to improve the properties of the parent drug and decrease the pre-systemic metabolism.[1,2] Many successful examples have been reviewed in the literature.[1-3] A detailed discussion of prodrugs and their active metabolites (parent drugs) is beyond the scope of this tutorial. Here we focus on the pharmacokinetics of a prodrug and its metabolite to help understand their pharmacokinetic data obtained from preclinical and clinical studies. This will ultimately help define the proper dose of the prodrug needed for efficacy.

Theoretical Analysis

Prodrug Kinetics

When a prodrug is administered orally, it undergoes complicated processes of absorption, distribution, metabolism, and excretion. To understand these processes for metabolites, Cummings and Martin published results on the excretion and accrual of drug metabolites in 1963.[4] This provides the basis for the pharmacokinetics of drug and its metabolites and can be readily applied to study the pharmacokinetics of prodrug. Since then, many theoretical analyses and reviews, related to prodrug pharmacokinetics, have been published.[5-10] A thorough understanding of prodrug kinetics is daunting and may be achieved using sophisticated physiologically based pharmacokinetic (PBPK) modeling.[11,12]

To get some insight pertinent to prodrug kinetics, we consider a simple scheme for the fate of a prodrug (P) after intravenous administration (Fig. 1). A fraction of the prodrug (f) is metabolized and produces a parent drug (D) with a first-order formation rate constant, $k_f(D)$. The drug (D) may be further metabolized to a daughter metabolite (DM$_1$) or excreted. The elimination rate constant of the parent drug, $k_{el(D)}$, is expressed by the sum of the formation rate constant of the daughter metabolite, $k_{f(DM1)}$, and the urinary excretion rate constant, $k_{ex(D)}$. More than one metabolite may be formed with a formation rate constant, $k_{f(PM2)}$, and then excreted with a rate constant, $k_{ex(PM2)}$. Otherwise, a fraction of the drug is excreted into urine as unchanged form (P) with a rate constant, $k_{ex(P)}$. The overall
Pharmacokinetics of prodrug and metabolite

elimination rate constant of the prodrug, $k_{\text{elP}}$, is the sum of $k_{\text{elD}}$, $k_{\text{PM2}}$, and $k_{\text{exP}}$. No matter how complex the pathways may appear, the time course for the change of metabolite amount can be described by a general relationship: rate of change of metabolite amount in body = rate of formation – rate of elimination. [5,6] However, a full mathematical description of this model is still complex and difficult to solve. We will further simplify this model to have clear understanding of the factors influencing the amount of parent drug in the body.

A basic model for prodrug kinetics

Consider a simple case of a two-step consecutive first-order irreversible reaction:

$$A \rightarrow^k B \rightarrow^k C$$

This model provides the basis for developing more complex models. Thus it is crucial to understand this reaction kinetics thoroughly for further study. Here, we use simple notations for the sake of clarity. We can set up the following three differential equations to describe the change in amounts of A, B, and C over time.

$$\frac{dA}{dt} = -k_1A$$
$$\frac{dB}{dt} = k_1A - k_2B$$
$$\frac{dC}{dt} = -k_2B$$

At $t = 0$, $A = A_0$, and $B = C = 0$, and $A + B + C = A_0$ at all times. The Eq. (1) can be solved immediately to give

$$A = A_0e^{-k_1t}$$

Substituting Eq. (4) into Eq. (2), we get

$$\frac{dB}{dt} + k_2B = k_1A_0e^{-k_1t}$$

Eq. (5) can be solved simply by noting that

$$\frac{d}{dt}(Be^{kt}) = (\frac{dB}{dt} + k_1B)e^{kt}$$

By multiplying both sides of Eq. (5) by $e^{kt}$ and using the above relationship, we get

$$d(Be^{kt}) = k_1A_0(e^{kt} - e^{-k_1t})$$

If $k_1 \neq k_2$, integration of Eq. (6) from $t = 0$ to $t$ gives

$$B = \frac{k_1A_0}{k_2 - k_1}(e^{kt} - e^{-k_1t})$$

In the special case when $k_1 = k_2$, Eq. (6) can reduce to

$$d(Be^{kt}) = k_1A_0 dt.$$ Then, the integrated expression becomes

$$B = k_1A_0 t e^{-k_1t}.$$ The expression for C can be obtained using the mass balance relationship, $C = A_0 - A - B$,

$$C = \frac{d}{dt}\left((k_2 - k_1) + k_1e^{-k_1t} - k_2e^{-k_1t}\right)$$

Figure 2 shows a typical amount-time profile of each species for the consecutive first-order irreversible reaction. The amount of A decreases at the normal exponential rate characteristic of a first-order decay curve (blue line). The amount of B follows a bi-exponential profile, first rising and then declining (red line). The amount of C continuously increases and reaches a plateau (green line). This profile is useful for quantifying absorption and elimination processes of drug as well as formation and elimination processes of metabolite.[13,14]

To calculate the maximum amount of B ($B_{\text{max}}$) and the time to reach the peak ($t_{\text{max}}$), we take the derivative of Eq. (7), set the derivative, $dB/dt$, to zero, and rearrange to obtain
Take the natural logarithm of both sides and solve for \( t_{\text{max}} \) to get

\[
B_{\text{max}} = \frac{e^{-k_1 t_{\text{max}}}}{k_1}
\]

The resulting \( B_{\text{max}} \) at \( t_{\text{max}} \) then becomes

\[
B_{\text{max}} = \frac{k_1 A_0}{k_2 - k_1} (e^{-k_2 t_{\text{max}}} - e^{-k_1 t_{\text{max}}})
\]

Using Eq. (10), we obtain

\[
B_{\text{max}} = A_0 e^{-k_2 t_{\text{max}}}
\]

From Eq. (11), we get

\[
-k_2 t_{\text{max}} = \frac{k_2 t_{\text{max}}}{k_2 - k_1} \ln \frac{k_2}{k_1}
\]

Therefore,

\[
B_{\text{max}} = A_0 \left( \frac{k_2}{k_1} \right)^{\frac{k_2}{k_1}}
\]

In Figure 2, we also visualized the Equations (11), (13), and (14) to show that \( t_{\text{max}} \) decreases and \( B_{\text{max}} \) increases as the ratio of \( k_1 \) to \( k_2 \) increases (dashed line). In other words, when \( k_2 \) is smaller than \( k_1 \), the amount of A quickly decreases while the amount of \( B \) increases rapidly, reaches a maximum at a shorter time, and then falls off with time.

**Plasma concentration profile after intravenous administration of prodrug**

Now consider a case for the intravenous administration of prodrugs \((P)\) in which all the prodrugs are converted to active drugs \((D)\) and then eliminated. In this case, the first-order formation rate constant for \( D \), \( k_{\text{a}(D)} \), is equal to the elimination rate constant for \( P \), \( k_{\text{a}(P)} \). The parameter \( k_{\text{a}(D)} \) represents the first order elimination rate constant for \( D \). The rate of change of \( D \) in the blood is determined by the difference between the formation and the elimination rates. Because the level of each species in the blood is measured in concentration \([D] = D/V_P\), where \( V_P \) is the volume of distribution for \( D \), it is convenient to express Eq. (7) with the same unit. Then, using new notations \((k_1 \rightarrow k_{\text{a}(D)}; k_2 \rightarrow k_{\text{a}(P)})\), we get

\[
[D] = \frac{k_{\text{a}(P)} V_P [P]_0}{V_P (k_{\text{a}(P)} - k_{\text{a}(D)})} (e^{-k_{\text{a}(D)} t} - e^{-k_{\text{a}(P)} t})
\]

where \( V_P \) is the volume of distribution for \( P \), and \([P]_0\) is the initial concentration of \( P \) in the blood.

When plasma concentrations are measured as a function of time, the area under the concentration-time curve (AUC) is of great interest in pharmacokinetics. We can derive a useful relationship between AUC and clearance \((CL = k/V)\) by solving Eq. (2) using a concentration-time integral method. Writing Eq. (2) in new notations and taking the integral of both sides, we get

\[
V_P \int_0^t [D] = k_{\text{a}(P)} V_P [P]_0 \int_0^t dt - k_{\text{a}(D)} V_P \int_0^t [D] dt.
\]

Because \( D \) is not present in the body initially or at infinity, the left side becomes zero. Rearranging Eq. (16) and substituting \( k_{\text{a}(P)} = CL/P \) and \( k_{\text{a}(D)} = CL(D)/V_D \), we get

\[
\frac{\text{AUC}(D)}{\text{AUC}(P)} = \frac{k_{\text{a}(P)} V_P}{k_{\text{a}(D)} V_P} \frac{CL(P)}{CL(D)}
\]

This ratio is useful to study metabolic pathway and pharmacokinetic interactions.[8-10,13]

**Elimination rate-limited (ERL) and formation rate-limited (FRL) metabolism**

As shown in Eq. (15), the plasma drug concentration, \([D]\), at any given time is expressed by two exponential functions. Depending on the relationship between the prodrug and drug elimination rates, one term can become more dominant than the other. For a more detailed discussion, we consider two limiting situations. In the first situation, formation is a much faster process than elimination (ERL metabolism: \( k_{\text{a}(D)} > k_{\text{a}(P)} \)). In the second situation, formation proceeds much more slowly than elimination (FRL metabolism: \( k_{\text{a}(P)} < k_{\text{a}(D)} \)). To help understand the underlying kinetics, we simulated these situations to draw semi-logarithmic plots of plasma concentration versus time using Eq. (15) (Fig. 3).

In ERL metabolism, at large time, the first term approaches zero because \( k_{\text{a}(D)} > k_{\text{a}(P)} \), and Eq. (15) reduces to

\[
[D] = \frac{k_{\text{a}(P)} V_P [P]_0}{V_P (k_{\text{a}(P)} - k_{\text{a}(D)})} e^{-k_{\text{a}(D)} t}.
\]

Taking the logarithm to the base 10 of Eq. (18), we get

\[
\log [D] = \log \left( \frac{k_{\text{a}(P)} V_P [P]_0}{V_P (k_{\text{a}(P)} - k_{\text{a}(D)})} \right) - \frac{k_{\text{a}(P)} t}{2.303}.
\]
Thus, the semi-logarithmic plots of plasma concentration versus time become linear with a slope of \( \frac{k_{el}}{2.303} \) at large time. Back extrapolation (dashed line) of the elimination phase slope (red line) provides an estimate of \([D]_0\) which is the intercept of \( \frac{k_{el}V_p}{V_D(k_{el}+k_{fD})} \) (Fig. 3a). When \( k_{elD} \gg k_{fD} \) and \( V_p = V_D \), the intercept can be further reduced to \([P]_0\).

This situation is commonly encountered in the metabolism of many prodrugs.[10,15] An example is the metabolism of an antitrypanosomal compound (OSU-36) after an intravenous administration of its ester prodrug (OSU-40) to rat. The hydrolysis of OSU-40 was fast, and its concentrations declined rapidly with short half-life (4.8 min). Whereas, the concentrations of OSU-36, hydrolyzed from OSU-40, declined slowly with the half-life of 41.9 min. This was close to the elimination half-life of the preformed OSU-36 (43.9 min), directly administered to the systemic circulation by an intravenous injection.[15]

In FRL metabolism (\( k_{fD} < k_{elD} \)), at large time, Eq. (15) can be reduced in a similar way to give

\[
[P]_0 = \frac{k_{elD}V_p}{V_D(k_{elD}+k_{fD})}e^{-k_{fD}t}.
\]

The slope and intercept of the semi-logarithmic plot of plasma concentration versus time are \( \frac{-k_{elD}}{2.303} \) and \( \frac{-k_{fD}V_p}{V_D(k_{elD}+k_{fD})} \), respectively (Fig. 3b). In the elimination phase, thus, the concentration of the parent drug is governed by the prodrug formation rate, not by the prodrug elimination rate. Since \( k_{fD} < k_{elD} \), the intercept can be further reduced to

\[
\frac{V_p}{V_D} = \frac{k_{elD}}{k_{fD}}.
\]

The plasma prodrug concentration, \([P]\), at any given time is easily obtained from Eq. (4), and its final semi-logarithmic expression is

\[
\log[P] = \log([P]_0) - \frac{k_{elD}}{2.303} t.
\]

In equations (21) and (23), it is worthwhile to note that the slopes are the same, that is, the concentrations of the parent drug and prodrug decline in parallel (Fig. 3b). Because the parent drug is eliminated almost as soon as it is formed, the elimination rate is approximately equal to the formation rate. The above equation can also be used to plot the plasma concentration-time profile of a preformed D (D*) directly administered to the systemic circulation by an intravenous injection (dotted line). From Figure 3b, we can easily figure out that the half-life of the formed parent drug (ln 2/\( k_{elD} \)) in the elimination phase is longer than that of the preformed parent drug (ln 2/\( k_{elD} \)). The half-life of the formed parent drug reflects that of the prodrug (ln 2/\( k_{elD} \)).

The FRL metabolism is less encountered in prodrug kinetics but occasionally in metabolite kinetics.[10,13,16] One interesting example is the metabolism of 3'-azido-2',3'-dideoxy-5'-O-oxalatothymidine (AZT-Ac) to zidovudine, [3'-azido-2',3'-dideoxylthymidine (AZT)].[16] Only AZT was detected in

Figure 3. Semi-logarithmic concentration-time profile of a prodrug (P, blue line) and its formed metabolite (parent drug, D, red line). Simulations were performed using Microsoft Excel for three cases: (a) ERL metabolism where \( k_{fD} > k_{elD} \): \( k_{fD} = 5, k_{elD} = 1, \) and \( V_D = V_p = 1 \), (b) FRL metabolism where \( k_{fD} < k_{elD} \): \( k_{fD} = 1, k_{elD} = 5, \) and \( V_D = V_p = 1 \), and (c) FRL metabolism for \( V_P/V_D > k_{elD}/k_{fD} > 1 \): \( k_{fD} = 1, k_{elD} = 5, \) and \( V_D = 0.05, V_p = 1, \) and \( A_0 = 10 \). Back extrapolation (dashed line; plotted using Eq. (19) or (21)) of the elimination phase slope (red line) provides an estimate of \([D]_0\). The dotted line was plotted using Eq. (23) for the direct intravenous administration of a preformed (or synthesized) parent drug (D*) with the initial amount of D* \((D*0) = 10 \) in (b) and 0.5 in (c). See text for details.
plasma, indicating that the prodrug is rapidly hydrolyzed in vivo with a high elimination rate constant. Thus, the first step looks like proceeding according to ERL-metabolism. However, the concentrations of AZT metabolized from AZT-Ac ($t_{1/2} = 2.16$ h) declined more slowly than those of AZT from preformed AZT ($t_{1/2} = 0.96$ h). This means that the metabolic pathway proceeds according to FRL metabolism ($k_{aAZT} < k_{aAZT}$), as discussed above. This discrepancy may be explained by the presence of multiple pathways for AZT-Ac elimination (small $f$ in Fig. 1) or by the presence of another intermediate between AZT-Ac and AZT. Because AUC for AZT metabolized from AZT-Ac is slightly larger than that for AZT from preformed AZT at the same intravenous dose, the latter explanation looks more plausible.

In FRL metabolism, it is interesting to consider one more situation where $V_D/V_D > k_{f(D)}$ or $CL_{DP} > CL_{DP}$. As shown in Figure 3c, the intercept for the parent drug ($[D]_0$) is greater than that for the prodrug ($[P]_0$). This situation is encountered in the metabolic conversion of propranolol to naphthoxylactic acid (NLA) after single intravenous and oral doses.[17] The AUC of NLA was two times greater than that of propranolol after an intravenous dose of propranolol (4 mg) and ten times after a single oral dose (20 or 80 mg). This can be easily explained if the volume of distribution of NLA is much smaller than that of propranolol. The volumes of distribution of basic drugs are often larger than 100 L, while those of their acidic metabolites are close to 10–20 L.[13] Thus, this situation is expected to be common when a basic prodrug is converted to an acidic parent drug.

We described the prodrug kinetics for the simplest situation: formation and sequential elimination. We can consider a more complicated model to account for more realistic situations but will lose simplicity by including more terms in equations. A more detailed discussion is beyond the scope of this tutorial. For further study, we recommend to read articles and book chapters in the References section.

Acknowledgements

This study was supported by a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI14C2750).

Conflicts of interests

Authors: The authors have no conflicts of interest to declare.

Editors: Nothing to declare

References

1. Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Järvinen T, et al. Prodrugs: design and clinical applications. Nat Rev Drug Discov 2008;7:255-270. doi: 10.1038/hdrd2468.

2. Zawiliska JB, Wojcieszak J, Olejniczak AB. Prodrugs: a challenge for the drug development. Pharmaco Rep 2013;65:1-14.

3. Obach RS. Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy. Pharmacol Rev 2013;65:578-640. doi: 10.1124/pr.111.005439.

4. Cummings AJ, Martin BK. Excretion and the accrual of drug metabolites. Nature 1963;200:1296-1297.

5. Martin BK. Kinetic considerations relating to the use of drug precursors. Br J Pharmaco Chemother 1967;31:420-434.

6. Houston JB. Drug metabolite kinetics. Pharmacol Ther 1982;15:521-552.

7. Houston JB, Taylor G. Drug metabolite concentration-time profiles: influence of route of drug administration. Br J Clin Pharmacol 1984;17:385-394.

8. Pang KS. A review of metabolite kinetics. J Pharmacokinet Biopharm 1985;13:633-662.

9. Smith PC. Pharmacokinetics of drug metabolites. In: Pearson PG, Wienkers LC (Eds.) Handbook of drug metabolism, 2nd ed. Informa Healthcare, New York, 2009;17-59.

10. de Campos ML, Padilha EC, Peccinini RG. A review of pharmacokinetic parameters of metabolites and prodrugs. Drug Metab Lett 2014;7:105-116.

11. Yang QJ, Pang KS. PBPK modeling to estimate metabolite formation from first-pass organs: intestine and liver. In: Chackalamannil S, Rotella D, Ward S, (Eds.) Comprehensive medicinal chemistry III, Volume 4, Elsevier, Oxford, 2013:81-101.

12. Sun H, Pang KS. Disparity in intestine disposition between formed and preformed metabolites and implications: a theoretical study. Drug Metab Dispos 2009;37:187-202. doi: 10.1124/dmd.108.022483.

13. Rowland M, Tozer TN. Clinical pharmacokinetics and pharmacodynamics: concepts and applications, 4th ed. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, 2011;603-632.

14. Atkinson AJ, Huang S-M, Lertora JLI, Markey SP, (Eds.) Principles of Clinical Pharmacology, 3rd ed. Academic Press, Amsterdam, 2012; 41-55.

15. Gershkovich P, Wasan KM, Silvak O, Lysakowski S, Reid C, Premalatha K, et al. Simultaneous determination of a novel antitrypanosomal compound (OSU-36) and its ester derivative (OSU-40) in plasma by HPLC: application to first pharmacokinetic study in rats. J Pharm Pharmacol Sci 2011;14:36-45.

16. Quevedo MA, Britón MC. In vitro and in vivo pharmacokinetic characterization of two novel prodrugs of zidovudine. Antiviral Res 2009;83:103-111. doi: 10.1016/j.antiviral.2009.03.010.

17. Walle T, Conradi EC, Walle UK, Fagan TC, Gaffney TE. Naphthoxylactic acid after single and long-term doses of propranolol. Clin Pharmacol Ther 1979;26:548-554.